What is Artelo Biosciences, Inc. (ARTL) stock price today?

Artelo Biosciences, Inc. (ARTL) is currently trading at $3.26, down 3.26% today.

What is ARTL P/E ratio?

Artelo Biosciences, Inc.'s P/E ratio is -0.05. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ARTL return on equity (ROE)?

Artelo Biosciences, Inc.'s return on equity (ROE) is -519.09%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Artelo Biosciences, Inc.'s market cap?

Artelo Biosciences, Inc. has a market capitalization of $1.26M.

NASDAQ · Biotechnology

Artelo Biosciences, Inc. (ARTL) Stock

$3.26 -3.26% NASDAQ: ARTL Healthcare

Valuation

Metric	Value
Price	$3.26
Market Cap	$1.26M
P/E Ratio	-0.05
P/B Ratio	0.21
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$179.19
52-Week Low	$3.23
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-519.09%
ROA	-196.18%
ROCE	-221.20%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	0.25

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-7.0M	$-10.0M	$-10.0M	$-10.0M	$-11.0M
Net Profit	$-7.0M	$-10.0M	$-9.0M	$-10.0M	$-13.0M
EPS	$-17.91	$-10.47	$-9.42	$-9.15	$-49.23
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$13.0M	$20.0M	$13.0M	$5.0M	$3.0M
Total Liabilities	$1.0M	$1.0M	$1.0M	$2.0M	$4.0M
Cash	$7.0M	$7.0M	$3.0M	$2.0M	$1.0M
Borrowings	$0	$0	$0	$0	$1.0M

Latest News

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury GlobeNewswire · Jul 1, 2026 Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 GlobeNewswire · Jun 30, 2026 Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 GlobeNewswire · Jun 29, 2026 Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success GlobeNewswire · Jun 10, 2026 Top Premarket Decliners MT Newswires · May 27, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-6.0M	$-8.0M	$-8.0M	$-8.0M	$-9.0M
Investing Cash Flow	$-3.0M	$3.0M	$4.0M	$8.0M	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$4.0M	$-5.0M	$-4.0M	$0	$-2.0M
Free Cash Flow	$-6.0M	$-8.0M	$-8.0M	$-8.0M	$-9.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.23
FCF Yield	-929.33%
Quick Ratio	3.00
Interest Coverage	-17.91
Return 1Y	-97.61%
Return 3Y	-96.77%
Return 5Y	-99.57%

Ownership

Insiders Held2.47%

Institutions Held8.10%

Institutions Float Held8.31%

Institutional Holder	Shares	Report Date
Kathmere Capital Management, Llc	13,250	2026-03-31
Jane Street Group, LLC	13,079	2026-03-31
Vanguard Capital Management LLC	10,129	2026-03-31
Vanguard Fiduciary Trust Co	3,139	2026-03-31
Citigroup Inc.	3,076	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
CARMCarisma Therapeutics, Inc.	$0.01	-5.17%	0.01	$230148	0.00%
GTBPGT Biopharma, Inc.	$6.68	+12.08%	-0.06	$8.43M	0.00%
LIPOLipella Pharmaceuticals Inc.	$0.07	+0.00%	-0.05	$300354	0.00%
PBMPsyence Biomedical Ltd.	$4.97	-2.93%	-0.41	$94524	0.00%
PTIXProtagenic Therapeutics, Inc.	$0.26	+18.18%	-0.08	$470654	0.00%

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc. is led by CEO Gregory D. Gorgas, publicly traded since 2019.

Artelo Biosciences, Inc. (ARTL) stock trades at $3.26 with a market capitalization of $1.26M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.21, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.23 and $179.19, and currently trades 98.2% below its 52-week high.

On profitability, Artelo Biosciences, Inc. generates a return on equity (ROE) of -519.09%, return on capital employed of -221.20%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides